search
Back to results

Evaluation of the Effect of Neurofeedback Targeting EEG Theta / Beta Activities on the Strengthening of Wakefulness Maintenance Capacities and Cognitive Performance. (NEUROWAKE)

Primary Purpose

Sleep Deprivation

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Neurofeedback
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Sleep Deprivation focused on measuring Neurofeedback; electroencephalography; sleep deprivation; maintenance wakefulness test; cognitive performance; learning modulation; arousal system.

Eligibility Criteria

18 Years - 35 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male or female aged between 18 and 35 years old,
  • Healthy subject, no pathology reported at the interview
  • Absence of EDS complaints (total ESS score<11) and sleep complaints (total Insomnia Severity Indexscore <15)
  • Presence of an objective EDS measured by a mean sleep latency of less than 30 minutes on the wakefulness maintenance test performed after a night of total sleep deprivation under controlled conditions (at the inclusion visit),
  • Motivated to carry out the program of 8 neurofeedback sessions,
  • Body mass index < 25 kg/m2,
  • Affiliated with the social security (beneficiary or entitled person),
  • Having been informed and having signed an informed consent.

Exclusion Criteria:

  • All pathologies that may induce excessive daytime sleepiness: untreated narcolepsy or idiopathic hypersomnia, untreated sleep apnea syndrome, untreated restless legs syndrome, untreated periodic leg movement syndrome, unstabilized psychiatric disorders of the characterized depressive disorder type, anxiety disorders, bipolar disorder, addictive disorders (alcohol and drugs), obesity having undergone surgical treatment for less than 3 months.
  • Chronic insomnia disorder
  • Excessive consumption of coffee, tea, or caffeinated cola type beverages (> 5 cups/day)
  • All pathologies making interaction with the neurofeedback device potentially problematic: intellectual, visual, auditory or motor impairment, psychotic disorders, unstable cardio-respiratory diseases, neurological disease of the central nervous system, confusion, dementia,
  • Any situation or treatment modifying the EEG spectral power: psychotropic treatments, night or shift work, chrono-biological disorders interfering with the level of daytime alertness, history of cranial surgery, epilepsy,
  • Pregnant or breastfeeding woman,
  • Persons placed under the safeguard of justice,
  • A person participating in another research study with an exclusion period still in progress,
  • Person whose physical and/or psychological health is severely impaired

Sites / Locations

  • CHU de BordeauxRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Neurofeedback participants

Arm Description

All the participants studied.

Outcomes

Primary Outcome Measures

Maintenance Wakefulness Test
Mean latency on the Maintenance Wakefulness Test (MWT) after a full night of sleep deprivation.

Secondary Outcome Measures

Karolinska Sleepiness Scale
Subjective daytime wakefulness level. minimum value 1 (extremely alert); maximum value 9 (extremely sleepy, fighting sleep)
Cognitive performance (1)
Psychomotor Vigilance Task (PVT),
Cognitive performance (2)
Test of Attention Performance (TAP)

Full Information

First Posted
October 13, 2020
Last Updated
January 9, 2023
Sponsor
University Hospital, Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT04591314
Brief Title
Evaluation of the Effect of Neurofeedback Targeting EEG Theta / Beta Activities on the Strengthening of Wakefulness Maintenance Capacities and Cognitive Performance.
Acronym
NEUROWAKE
Official Title
Evaluation of the Effect of Neurofeedback Targeting EEG Theta / Beta Activities on the Strengthening of Wakefulness Maintenance Capacities and Cognitive Performance.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 6, 2023 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Neurofeedback is a cognitive remediation technique that allows a subject to learn to regulate their cognitive and brain activity through information provided in real time about their brain activity, in particular electroencephalographic (EEG) brain activity. Neurofeedback could, through its impact on the degree of neuronal synchronization, help to reduce the impact of sleep deprivation on wakefulness and cognitive performance. The main objective is to study the effect of a program of 8 sessions of neurofeedback targeting EEG theta / beta activities, to modify the degree of neuronal synchronization, on the ability to maintain objective wakefulness measured by a maintenance wakefulness test (MWT) in healthy subjects presenting objective excessive daytime sleepiness after a full night of sleep deprivation under controlled experimental conditions. The objective of this study will also provide a better understanding of the learning modulation mechanisms of arousal systems.
Detailed Description
Neurofeedback is a cognitive remediation technique that allows a subject to learn to regulate their cognitive and brain activity through information provided in real time about their brain activity, in particular electroencephalographic (EEG) brain activity. Neurofeedback has been used to regulate EEG amplitude in certain spectral bands, which correlate with the degree of neural synchronization. Neurofeedback makes it possible in particular to reduce the amplitude of the EEG theta spectral band (4-8 Hz) and to increase the EEG beta spectral band (> 12Hz). This type of protocol has been used successfully to reduce the degree of neural synchronization and to stimulate arousal systems and sustained attention skills. Studies on healthy subjects submitted to controlled sleep deprivation have shown that inducing a full night of sleep deprivation is a good model for studying the brain mechanisms of arousal and the links with cognitive functions, but also to assess the effectiveness of counter measures reducing the impact of sleep deprivation on cognitive performance. These experimental models provide a better understanding of the mechanisms and consequences of the complaint of excessive daytime sleepiness (EDS). EDS is indeed a frequent symptom affecting between 5% and 8% of the population. The consequence of EDS is a decrease in quality of life. In addition, the EDS entails a high medico-economic cost because of the accidental risk of the public and professional roads. Neurofeedback could, through its impact on the degree of neuronal synchronization, help to reduce the impact of sleep deprivation on wakefulness and cognitive performance. Thus, it appears relevant to assess the effectiveness of neurofeedback, targeting activities in the theta / beta EEG spectral band, on wakefulness and cognitive performance in healthy subjects with EDS due to sleep deprivation. Targeting the degree of neuronal EEG synchronization would then be an innovative avenue for improving the physiological mobilization of arousal systems and wakefulness and cognitive performance in the event of EDS. This cognitive remediation technique could in particular be proposed as a complement to pharmacological treatment in treated patients suffering from hypersomnolence disorder presenting a residual EDS. The main objective is to study the effect of a program of 8 sessions of neurofeedback targeting EEG theta / beta activities, to modify the degree of neuronal synchronization, on the ability to maintain objective wakefulness measured by a maintenance wakefulness test (MWT) in healthy subjects presenting objective excessive daytime sleepiness after a full night of sleep deprivation under controlled experimental conditions. The objective of this study will also provide a better understanding of the learning modulation mechanisms of arousal systems. The secondary objectives are: To study the effect of a program of 8 sessions of neurofeedback targeting theta / beta EEG activities, in healthy subjects after a full night of sleep deprivation presenting objective excessive daytime sleepiness, on the instantaneous subjective arousal level in a situation controlled (MWT and neurofeedback session) by the Karolinska sleepiness scale (KSS). To study the effect of a program of 8 sessions of neurofeedback targeting theta / beta EEG activities, in healthy subjects after a full night of sleep deprivation presenting objective excessive daytime sleepiness, on the cognitive performance, before and after neurofeedback sessions, assessed by the Psychomotor Vigilance Task (PVT) and by the Test of Attentional Performance (TAP). To study the functional reorganization of the EEG activities of the brain, in particular the degree of neuronal synchronization between the different regions of the scalp, in subjects presenting objective excessive daytime sleepiness after a full night of sleep deprivation and following a program of 8 neurofeedback sessions targeting EEG theta / beta activities. To study a learning effect during the 8 neurofeedback sessions evaluated by measuring the evolution of the modulation of the spectral power in the theta / beta band during each neurofeedback session. To study the prognostic learning factors during the 8 neurofeedback sessions. To study the prognostic factors for clinical improvement of MWT, subjective EDS and cognitive performance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Deprivation
Keywords
Neurofeedback; electroencephalography; sleep deprivation; maintenance wakefulness test; cognitive performance; learning modulation; arousal system.

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Neurofeedback participants
Arm Type
Experimental
Arm Description
All the participants studied.
Intervention Type
Behavioral
Intervention Name(s)
Neurofeedback
Intervention Description
The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
Primary Outcome Measure Information:
Title
Maintenance Wakefulness Test
Description
Mean latency on the Maintenance Wakefulness Test (MWT) after a full night of sleep deprivation.
Time Frame
1 week after the end of the neurofeedback program (6 weeks after inclusion [day 0])
Secondary Outcome Measure Information:
Title
Karolinska Sleepiness Scale
Description
Subjective daytime wakefulness level. minimum value 1 (extremely alert); maximum value 9 (extremely sleepy, fighting sleep)
Time Frame
At inclusion [day 0], each neurofeedback sessions (weeks 1,2,3,4,5), and 1 week after the end of the neurofeedback program (6 weeks after inclusion [day 0])
Title
Cognitive performance (1)
Description
Psychomotor Vigilance Task (PVT),
Time Frame
At inclusion [day 0] and 1 week after the end of the neurofeedback program (6 weeks after inclusion [day 0])
Title
Cognitive performance (2)
Description
Test of Attention Performance (TAP)
Time Frame
At inclusion [day 0] and 1 week after the end of the neurofeedback program (6 weeks after inclusion [day 0])

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female aged between 18 and 35 years old, Healthy subject, no pathology reported at the interview Absence of EDS complaints (total ESS score<11) and sleep complaints (total Insomnia Severity Indexscore <15) Presence of an objective EDS measured by a mean sleep latency of less than 30 minutes on the wakefulness maintenance test performed after a night of total sleep deprivation under controlled conditions (at the inclusion visit), Motivated to carry out the program of 8 neurofeedback sessions, Body mass index < 25 kg/m2, Affiliated with the social security (beneficiary or entitled person), Having been informed and having signed an informed consent. Exclusion Criteria: All pathologies that may induce excessive daytime sleepiness: untreated narcolepsy or idiopathic hypersomnia, untreated sleep apnea syndrome, untreated restless legs syndrome, untreated periodic leg movement syndrome, unstabilized psychiatric disorders of the characterized depressive disorder type, anxiety disorders, bipolar disorder, addictive disorders (alcohol and drugs), obesity having undergone surgical treatment for less than 3 months. Chronic insomnia disorder Excessive consumption of coffee, tea, or caffeinated cola type beverages (> 5 cups/day) All pathologies making interaction with the neurofeedback device potentially problematic: intellectual, visual, auditory or motor impairment, psychotic disorders, unstable cardio-respiratory diseases, neurological disease of the central nervous system, confusion, dementia, Any situation or treatment modifying the EEG spectral power: psychotropic treatments, night or shift work, chrono-biological disorders interfering with the level of daytime alertness, history of cranial surgery, epilepsy, Pregnant or breastfeeding woman, Persons placed under the safeguard of justice, A person participating in another research study with an exclusion period still in progress, Person whose physical and/or psychological health is severely impaired
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Arthur MICOULAUD-FRANCHI, Dr
Phone
0557820182
Ext
+33
Email
jarthur.micoulaud@gmail.com
Facility Information:
Facility Name
CHU de Bordeaux
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Arthur MICOULAUD-FRANCHI, Dr
Phone
0557820182
Email
jarthur.micoulaud@gmail.com
First Name & Middle Initial & Last Name & Degree
Cécile Klochendler
Phone
0557820182
Email
cecile.klochendler@chu-bordeaux.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of the Effect of Neurofeedback Targeting EEG Theta / Beta Activities on the Strengthening of Wakefulness Maintenance Capacities and Cognitive Performance.

We'll reach out to this number within 24 hrs